Quantum Biopharma (NASDAQ:QNTM) Rating Lowered to Sell at Wall Street Zen

Quantum Biopharma (NASDAQ:QNTM) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Quantum Biopharma presently has an average rating of “Sell”.

Quantum Biopharma Stock Performance

QNTM stock opened at $6.18 on Friday. The stock has a market capitalization of $23.61 million, a PE ratio of -0.57 and a beta of 0.24. Quantum Biopharma has a one year low of $2.89 and a one year high of $38.25. The company has a fifty day moving average of $8.14 and a 200-day moving average of $14.16.

Quantum Biopharma (NASDAQ:QNTM) last announced its quarterly earnings results on Friday, November 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.05). Equities analysts forecast that Quantum Biopharma will post -3.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Quantum Biopharma stock. Steward Partners Investment Advisory LLC bought a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned 0.11% of Quantum Biopharma at the end of the most recent reporting period. 1.24% of the stock is owned by institutional investors.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.